Skip to main content
Premium Trial:

Request an Annual Quote

Software Firm Proventys Raises $3.3M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software firm Proventys has raised nearly $3.3 million in an offering it hopes will bring in a total of $5.1 million, the firm said in a document filed with the US Securities and Exchange Commission.

The company did not say how the funds would be used.

A total of seven individuals participated in the offering including current Proventys directors Ralph Synderman, Proventys' founder and chairman of the board; Steven Burrill, CEO of VC firm Burrill & Co.; and David Lawrence, former CEO and chairman of Kaiser Foundation Health Plan and Kaiser Foundation Hospitals.

Proventys is based in Durham, NC, and according to its website, its main platform, called the Proventys PDx System, incorporates statistical models that leverage clinical data and biomarkers to quantify a patient's chances of developing a disease or adverse event, or predict response to a therapy.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.